Could Dormancy Allow Lyme Disease to Survive Antibiotics?
Lyme disease dormancy antibiotics research suggests that some forms of B. burgdorferi may survive treatment by entering low-activity states.
Feng and colleagues from Johns Hopkins University identified FDA-approved drug combinations that may be effective against B. burgdorferi persisters in vitro.
Persistence may represent one form of bacterial dormancy. “Evidence suggests dormancy consists of a continuum of interrelated states including viable but nonculturable (VBNC) and persistence states,” according to Mali.
These states may contribute to antibiotic tolerance, latent infection, and potential reemergence after treatment.
Persister Cells and VBNC States
Mali distinguishes between two key dormant states:
- Persister cells: A small subpopulation that enters a dormant, nondividing state but can resume growth after stress resolves
- VBNC cells: Living cells that cannot grow on routine culture media and require specific signals to reactivate
Both states may allow bacteria to survive antibiotic exposure and contribute to reduced metabolic activity.
Why Dormancy Matters in Lyme Disease
Lyme disease dormancy antibiotics research raises important questions about treatment response.
Persister and VBNC cells may coexist, contributing to antibiotic tolerance and possible symptom persistence.
These findings may help explain why some patients continue to experience symptoms after treatment.
Learn more about post-treatment Lyme disease syndrome (PTLDS) and the role of coinfections in persistent illness.
Future Directions
Understanding dormancy may lead to identification of proteins and pathways that drive these states.
This could support the development of therapies targeting dormant bacterial forms.
Clinical Perspective
Lyme disease dormancy antibiotics remains an area of ongoing research.
While in vitro findings are promising, further clinical studies are needed to determine how these mechanisms affect patient outcomes.
Clinical Takeaway
Lyme disease dormancy antibiotics research suggests that dormant bacterial states may contribute to survival under treatment.
Further research may clarify their role in persistent symptoms and guide future therapies.
References
- Mali S, et al. J Bacteriol. 2017.
- Feng J, Auwaerter PG, Zhang Y. PLoS One. 2015.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
Obviously.
You don’t reference Kim Lewis’ fantastic work on B. burgdorferi persisters at Northeastern.
I agree. Here is the link to the Northeastern article on persisters.
I’m getting your emails so I must be subscribed already
good